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Abstract
Background: The weight that gene copy number plays in transcription remains controversial; although in specific
cases gene expression correlates with copy number, the relationship cannot be inferred at the global level. We
hypothesized that genes steadily expressed by 15 melanoma cell lines (CMs) and their parental tissues (TMs)
should be critical for oncogenesis and their expression most frequently influenced by their respective copy
number.
Results: Functional interpretation of 3,030 transcripts concordantly expressed (Pearson’s correlation coefficient
p-value < 0.05) by CMs and TMs confirmed an enrichment of functions crucial to oncogenesis. Among them, 968
were expressed according to the transcriptional efficiency predicted by copy number analysis (Pearson’s correlation
coefficient p-value < 0.05). We named these genes, “genomic delegates” as they represent at the transcriptional
level the genetic footprint of individual cancers. We then tested whether the genes could categorize 112
melanoma metastases. Two divergent phenotypes were observed: one with prevalent expression of cancer testis
antigens, enhanced cyclin activity, WNT signaling, and a Th17 immune phenotype (Class A). This phenotype
expressed, therefore, transcripts previously associated to more aggressive cancer. The second class (B) prevalently
expressed genes associated with melanoma signaling including MITF, melanoma differentiation antigens, and
displayed a Th1 immune phenotype associated with better prognosis and likelihood to respond to
immunotherapy. An intermediate third class (C) was further identified. The three phenotypes were confirmed by
unsupervised principal component analysis.
Conclusions: This study suggests that clinically relevant phenotypes of melanoma can be retraced to stable
oncogenic properties of cancer cells linked to their genetic back bone, and offers a roadmap for uncovering novel
targets for tailored anti-cancer therapy.
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Background
Advanced melanoma remains one of the cancers with
the poorest prognosis [1,2] as patients can expect to live
less than 8 months on average once their disease metas-
tasizes [3]. In fact, metastatic melanoma’s genetic
instability poses a major challenge for the development
of targeted therapies. This is evidenced by the poor long
term outcomes observed when individual pathways are
targeted as alternate oncogenic mechanisms rapidly
develop and prevail [1,4,5]. Immunotherapy is also ham-
pered by unstable cancer cell phenotypes that rapidly
evolve under the selective pressure of immune effector
mechanisms [6,7]. Whole-genome studies have improved
our understanding of melanoma biology, but much more
needs to be discovered. For instance, a decade ago global
transcriptional profiling suggested that over-expression
of WNT5A denoted a highly aggressive melanoma phe-
notype associated with enhanced cellular motility [8].
Moreover, the poor prognosis phenotype was associated
with a more undifferentiated status with no expression of
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yet, this important functional insight failed to yield a use-
ful clinical application and a global understanding of
genetic determinants responsible for the two phenotypes
remains elusive.
Chromosomal aberrations are a common feature of
human cancers, are more pronounced in solid tumors
than hematologic cancers and occur with consistency in
malignant melanomas [9-12]. However the debate over
the role that chromosomal aneuploidy plays in cancer is
ongoing [9,13-15] and the relationship between alterations
in gene copy number and respective gene expression is
not clear-cut [16-19]. The transcriptional repercussions of
chromosomal copy number imbalances relies on their
influence on gene expression, but model systems, such as
cancer cell lines suggest a limited relationship [19]. Cancer
cell lines provide a non-invasive tool for studying funda-
mental aspects of human cancer biology and are easily
accessible for research [9]. However, cell lines, while pro-
viding information about stable features of cancer genetics,
do not inform about salient aspects of their biology in the
interactive tumor microenvironment and about potential
selection in vitro of non-representative sub-clones. This
study, therefore, was aimed at the identification of consis-
tent correlates between cell lines and parental tissues that
define stable principles of cancer biology valid in vitro and
in vivo. This may constitute an alternate roadmap to the
identification of relevant therapeutic targets.
We hypothesized that genes concordantly expressed by
parental tissues and their cell line progeny may embody
necessary elements for the maintenance of oncogenesis.
The concordance of expression may gradually decline
according to causality from transcripts driving (i.e. signal-
ing and cell cycle regulating molecules), to those asso-
ciated with oncogenesis (i.e. cancer testis antigens), and to
those related to the ontogeny of melanoma (i.e.m e l a n o m a
differentiation antigens). We also reasoned that, if such
hierarchy existed, transcripts with highest concordance of
expression between tissues and cell lines should also be
most likely to be affected by genetic factors driving the
oncogenic process including aneuploidy. Thus, we tested
the degree with which transcripts stably expressed by can-
cer cells in vivo and in vitro matched in expression the
prediction suggested by the corresponding amplification
or deletion at the respective gene. Having identified a set
of genes that matched this requirement we explored
whether their expression in 112 melanoma metastases
could be related to previous taxonomic classification of
melanoma [8]. Two divergent phenotypes of melanoma
were observed. The first phenotype was characterized by
prevalent expression of cancer testis antigens, WNT5A
and a Th17 immune phenotype; those characteristics have
all been ascribed to a more aggressive behavior of cancer
(Class A) [8,20-22]. A second phenotype (Class B) was
characterized by prevalent expression of melanoma differ-
entiation antigens and a Th1 immune phenotype; both
characteristics associated with better prognosis. A third
category sitting astride the two polar groups was also iden-
tified (Class C). Thus, this study links clinically relevant
transcriptional signatures of melanoma to stable onco-
genic properties of cancer cells and offers a road map for
uncovering novel targets of therapy.
Results
Genetic characterization of the 15 melanoma cell lines
With exception of copy number gains found on chromo-
some 19, CGH results were concordant with previous stu-
dies [9,19,23]. The most frequent regions of chromosomal
gain were in 1q, 6p, 7, 8q, 19, 20 and losses were observed
in 4q, 6q, 9, 10 (Figure 1A). Examination of gene-specific
loci provided estimates of the copy number for oncogenes
and tumor suppressors whose prevalence of genomic
imbalances had been previously described. As shown in
(Figure 1B), the imbalances observed are consistent with
the results of a recently published study by Gast et al. [23]
also examining metastatic melanoma. In all cases, gene-
specific amplifications or losses were in the same direction
between studies. Of 11 gene-specific imbalances only 2
(CCNEI, CDK4) resulted amplified at a higher rate in our
study. This discrepancy migh tb ed u et ot r u eb i o l o g i c a l
differences between samples analyzed by the two studies
or may reflect technical biases related to the method of
analysis. Gast et al. [23] used the Hidden Markov Model
(HMM) to calculate copy number which is based on defin-
ing integer states of ploidy. In this study, we used a seg-
m e n t a t i o n - b a s e dm e t h o dt h a t defines regions with copy
numbers imbalances based on signal to noise differences
compared to adjacent regions; this method is likely more
sensitive in detecting shorter intra-genic imbalances. For
instance, in the case of CDK4, we found 2 different copy
number states within the same gene in 4 of the 15 cell
lines (Figure 1C). One cell line showed two different copy
number states within the tumor suppressor gene
CDKN2A. These intra-genic shorter imbalances may
account for the higher rate of amplifications called by our
study that may not represent a true and functionally rele-
vant biological difference as only a proportion of the gene
is amplified. In spite of these minor discrepancies, CGH
confirmed that the melanoma cell lines studied align with
the current characterization of metastatic melanoma and
are, therefore, representative of the disease.
Functional genomics correlates between parental tissues
and derived cell lines: definition of cancer-specific
transcripts
With the assumption that genes stably expressed by cell
lines and parental tissues might be most relevant to the
survival and growth of cancer cells, we applied whole
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anoma tumors (TMs) and cell lines (CMs). PCA analysis
comparing TMs to CMs demonstrated that the cell lines
grown in identical culture conditions clustered homoge-
neously compared to the parental tumors (Figure 2A).
Moreover, there was little concordance in the transcrip-
tional patterns of autologous CMs and TMs (Figure 2B).
This could be expected as the transcriptional profile of
TMs included transcripts expressed by infiltrating normal
cells and variations in gene expression in cancer cells
reacting to micro-environmental stimuli absent in culture.
To test whether the expression of genes related to mela-
noma biology could match TM with the respective CM,
we sorted cancer testis antigens [24], melanoma differen-
tiation antigens [25,26], melanoma-restricted genes [26]
and cancer specific biomarkers expressed by cancerous
tissues in vivo but not normal tissues [27] from the com-
plete data set. This exercise demonstrated that the expres-
sion of cancer-restricted genes was consistent between 10
of 15 TM/CM pairs (Additional file 1: Figure S1). This
observation encouraged further identification of tran-
scripts stably expressed by CMs and TMs. Applying
Pearson’s correlation we compared the expression of indi-
vidual genes between TMs and CMs. At a cutoff p-value <
0.05 or < 0.01, we identified 3,030 or 1,006 genes respec-
tively (Figure 2C, gene list provided in Additional file 2:
Table S1). Hierarchical clustering based on the 1,006 gene
set demonstrated transcriptional proximity in 12 of 15
pairs (Figure 2D); moreover, duplicate cell lines derived
from the same lesions clustered together (thicker gray and
dark green brackets, Figure 2D). IPA suggested that the
top self-organizing network related to the 3,030 gene set
was centered on genetic disorders, metabolic disease and
cancer. The hubs of the network were VEGF, CDKN2A
and PTEN (Figure 2E). Top biological functions included
genetic disorders and cancer (p < 0.009, p < 0.01 respec-
tively, (Figure 2F). Similarly, top molecular and cellular
function pathways included cell cycle, gene expression,
cell death, cellular growth and proliferation and cellular
assembly and organization (p < 0.01 for all pathways).
These results confirmed that genes concordantly
expressed by CMs and TMs are primarily related to the
oncogenesis. To evaluate whether this strategy would also
enrich for housekeeping genes, we identified putative
Figure 1 (A) Whole genome view of chromosomal aberrations of 15 melanoma cell lines. Vertical lines represent individual samples.
Segments are defined by amplifications (red), deletions (blue), and regions unchanged with respect to diploid reference (green) (B) Chart
showing comparisons between select oncogenes and tumor suppressors in 15 melanoma cell lines compared to data published by Gast et al.
[23]. Asterisks denote genes where copy number state of gene was mixed, and a visual diagram of this phenomenon is illustrated in panel C. (C)
Examples of 2 genes that showed copy number aberrations intra-gene. CDKN2A showed 38% unchanged/62% deletion in 1 sample. CDK4
showed 53% unchanged/47% amplification in 3 samples, and 53% deletion/47% amplification in 1 sample.
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studies [28,29] and compared the ratio of their presence in
the whole data set compared to the ratio of those included
among the 3,030 (Additional file 3: Table S2). Of 408 puta-
tive housekeeping genes according to one reference [29]
(1.4% of the complete array data set), only a 56 were
included in the 3,000 genes (1.9%) and 19 in the 1,000
more stringent data set (1.9%). Thus only a modest enrich-
ment in housekeeping genes was observed. Of 48 genes
suggested by the other reference [28] (0.2% of the com-
plete data set, only 8 and 2 were included in the 3,000 and
1,000 gene data sets (0.3 and 0.2% respectively). Thus, it is
unlikely that the genes identified as stably expressed by
cancer cells in this analysis represent a significant propor-
tion of housekeeping genes.
As a measure of comparison, 3,000 genes that were
not correlated between TMs and CMs (Pearson’sy<
0.1) were randomly selected and analyzed via IPA. The
top network pathways in this cohort did not include any
cancer-related pathway. The top biological function
included genetic disorder, hematologic disease, connec-
tive tissue disorders, immunological disease, and
inflammatory disease (p < 0.01 for all pathways) (Data
not shown).
Correlation between gene copy number and
transcription: definition of “genomic delegates”
We previously observed that areas of genomic imbalances
are enriched (though limitedly) with transcripts whose
expression matches the prediction of the respective imbal-
ance [19]. With the hypothesis that stably expressed genes
should be preferentially linked to oncogenesis and, there-
fore, should be more closely dependent upon genomic fac-
tors for their expression including copy number variation,
we measured the correlation between copy number and
respective transcription in sequential subsets of genes
ranked according to 0.1 decrements in y value between
TM and CM expression. While most stably expressed
genes (y 0.5; p-value 0.05) displayed the highest level of
concordance with copy number direction, a gradual reduc-
tion was observed for lower ranking gene sets in percen-
tage of genes expressed in concordance with their
respective copy number (overall y = 0.97) (Figure 3A).
This observation supports the notion that stability of
Figure 2 PCA analysis based on the complete transciptional data set visualizing the tridimentsional distribution of cell lines (CM, pink)
compared to pair melanoma tumors (TM, yellow) (A) of the distribution of the samples according to the patient identity from which
either TMs or CMs were derived (B). (C) Venn diagram displaying the results of a Pearson’s correlation analysis of gene expression between
TMs and CMs (p-value cutoff < 0.05). (D) Self-organizing hierarchical tree based on the top 1,006 genes whose expression was most significantly
(p-value < 0.01) correlated between TMs light green) and CMs (light pink); sample ID refers to the patients from which either a TM or CM was
derived. Brackets underline autologous TM/CM pairs demonstrating a comparable expression pattern. (E) Top functional network generated by
Ingenuity Pathway Analysis (IPA) http://www.ingenuity.com based on the 3,030 target genes. (F) Bar graph demonstrating the top biological
functions of the 3,030 target genes according to IPA.
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lines is a reasonable method to search for genes whose
expression is directly or indirectly related to structural
alterations of the genome.
Of the 3,030 genes stably expressed between TMs and
CMs, only 968 (32%) were concordant (significance cutoff
p < 0.05) with their respective genomic imbalance (Figure
3B, gene list provided in Additional file 2: Table S1) con-
firming previous estimates [19]; we refer to them as “geno-
mic delegates” as they represent in expression the genetic
footprint of individual cancers. IPA revealed that these
genes are tightly related to oncogenesis (Figure 3C). The
location of the delegate genes spanned the entire genome
a n di n c l u d e dc o p yn u m b e rg ains (34%) and deletions
(14%), while approximately half of the stably expressed
genes (52%) belonged to genomic regions with no copy
number change (Figure 3D). We then tested whether the
expression of the delegate genes could segregate autolo-
gous TM/CM pairs in harmony (Figure 3E). Although the
set of delegate genes was derived from the lower strin-
gency 3,030 gene pool, which could not pair CMs with
TMs as well as the higher stringency pool of 1,000 genes
(Figure 3E), hierarchical clustering of the 968 delegate
genes (based on concordance with genetic imbalances)
yielded results similar to the higher stringency cluster ana-
lysis revealing that 11 CMs paired with their parental TM.
The frequency of putative housekeeping genes was 2.2%
and 0% according to the two respective references [28,30]
Figure 3 (A) (Left panel) percent of transcripts whose expression correlates with its respective copy number in different sets of genes
ranked in .1 decrements of correlation (y value) in expression between CMs and TMs; significant correlation between RNA expression
and DNA copy number set at a Pearson’s correlation cutoff p-value of < 0.05. The number of genes included in each gene set is shown in
the right panel. (B) Venn diagram displaying the number of transcripts among the complete genome whose expression is consistent between
CMs and TMs and correlates with copy number. (C) Bar graph demonstrating the top biological functions of the 968 target genes analyzed with
Ingenuity Pathway Analysis http://www.ingenuity.com. (D) Top: Chromosomal view of the location of the 968 target genes mapped to their
location within the genome. Copy number states are shown per sample for amplifications (red), deletions (blue), and unchanged regions (green);
Bottom: Histogram depicting the number of the 968 target genes per chromosome. (E) - Self organizing clustering of CMs and TMs based on
the 968 delegate transcripts. Sample ID refers to the patients from whom either CMs or TMs were derived. A, B and C refer to TARA’s
classification as discussed in the text.
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related to basic cell metabolism resulted from this strategy.
Functional relevance of delegate genes
We then tested whether the 968 genomic delegates could
point to subclasses of melanoma metastases linked to
structural alterations of the cancer cell genome. We, there-
fore, used these genes as the basis for a self-organizing
clustering of 112 melanoma metastases (Figure 4A). This
analysis identified two divergent clusters with a third inter-
m e d i a t es u b - c l u s t e r .W ec l a s s ified individual metastases
belonging to each cluster as TARA (transcriptional adjust-
ments related to amplifcification/deletion) class A, B or C.
Comparison between class A and B metastases identified
18,460 transcripts differentially expressed at a p-value cut-
off of < 0.001. Selection of the top 100 transcripts discri-
minating class A from B was used to reshuffle the 112
melanoma samples. This high stringency selection
revealed that the C class included metastases that fre-
quently but not exclusively clustered closer to the A class.
To test whether this segregation was strictly defined by
the delegate genes or represented a broader phenotype of
melanoma metastases, we applied PCA to the complete
data set. The assignment of the individual metastases to
the three classes accurately predicted their distribution in
three-dimensional space suggesting that the three pheno-
types occur naturally in vivo (Figure 4B) although a core
of their transcriptional signature can be retraced to struc-
tural alterations of the genetic back bone of individual
cancers. Canonical pathway analysis based on the 18,460
transcripts demonstrated enrichment of genes associated
with cell cycle regulation and cell division (Figure 4C);
functional annotations included, in addition to those asso-
ciated with cancer, others associated with innate immunity
(Figure 4D). To gain insights about the functional rele-
vance of the different TARA classes, we sorted from the
complete data set genes known to be relevant to mela-
noma oncogenesis and observed their behavior in a self-
organizing cluster (Figure 4E). This analysis demonstrated
that the large majority of genes classically associated with
melanoma-specific processes along the MAP kinase path-
ways were up regulated in the B group while the A group
was characterized by a general deregulation of cyclins,
WNT and g-protein coupled receptor signaling. We also
tested the predictive value of a signature we proposed a
decade ago to differentiate melanoma metastases of an
aggressive nature [8] (Figure 4F). This signature accurately
separated Class B from the other classes demonstrating
that the delegate genes may reclassify melanomas accord-
ing to categories of potential prognostic value. In particu-
lar Wnt5A, which has been associated with enhanced
invasiveness in melanoma [8,20,21] was predominantly
down-regulated in the B compared with the A class and
conversely, MITF and melanoma differentiation antigens
were prevalently expressed by the B class melanomas.
Moreover, cancer testis antigens which are associated with
cancer de-differentiation were expressed predominantly by
the poor prognosis A class (Additional file 4: Figure S2)
confirming the observation that MAGE antigen expression
is associated with poorer prognosis in cancer [31,32].
Finally, the two classes of melanoma could be segregated
by signatures denoting Th1 or Th17 immune phenotypes
[22,33-35]. The Th1 type signature was restricted to a sub-
set of B class metastases while Th17 type signatures were
distinctive of the A group (Figure 4G). The suggestion
that melanoma metastases belonging to TARA’sC l a s sA
represent a less differentiated cancer phenotypes is also
supported by the observation that re-clustering of CMs
and TMs either by the 1,006 concordantly expressed
genes (Figure 2D) or the 968 genomic delegates (Figure
3E) was more effective in matching TARA’s Class B and C
pairs than A. Indeed all Class B pairs belonged to the
same cluster and almost universally matched while only 2
of four A pairs matched. This observation suggests that
genetic and transcriptional stability is a preferential prop-
erty of TARA Class B melanoma metastases.
Genetic basis determining TARA’s classification
Analyses of the genetic differences among the three classes
of melanoma or among the respective cell lines are being
undertaken to identify regions of potential interest for the
identification of novel oncogenes or tumor suppressor
genes. A preliminary analysis did not identify striking dif-
ferences between the two (class A vs class B) suggesting
that the distinct phenotypes cannot simply be attributed
to different levels of chromosomal instability and conse-
quent aneuploidy but to more specific alterations of the
genomic/transcriptomic axis that will require extensive
evaluation. In particular, there were no specific differences
in expression of microtubule depolymerases such as Kif2,
MCAK or other regulatory components of the kinetochore
[10] among the 15 cell lines ranked according to the segre-
gation of their parental tumors into the different TARA’s
classes; similarly, sequencing of c-KIT, BRAF, KRAS,
HRAS and NRAS did not identified specific polymorph-
isms or mutations that could explain the two phenotypes,
nor could the analysis of the individual gene copy number
(Additional file 5: Table S3).
Discussion
It has been suggested that gene copy number bears cau-
sation in oncogenesis [14,15] by directly or indirectly
influencing the transcriptional activity of individual genes
such as B-Raf [39-41]. It has also been suggested that
gene copy number can affect the global transcriptional
pattern of cancers; Pollack et al. observed [18] that breast
cancers could be equally segregated into subclasses either
according to the pattern of genomic imbalances or the
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However, the same study did not evaluate whether iden-
tical classification could be obtained by using genes not
included in the genomic imbalances as a basis for re-clus-
tering. When this was tested by a subsequent study, it
was observed that autologous cell lines segregated sepa-
rately from heterologous ones whether copy number
changes were used for re-clustering or whether the
expression of resident or non-resident genes was consid-
ered for re-clustering. This observation questioned
whether genomic imbalances influence transcription at
the global transcriptional level [13]. Thus, it remains
unclear to what extent genetic imbalances affect
transcription. Although at first glance it may seem intui-
tive that chromosomal gains should result in increased
expression and vice versa for chromosomal depletions
(loss of heterozygosity, homozygous deletion), on second
thought, it should not be surprising that this linear rela-
tionship may be overwhelmed by the complexity of gene
regulation. Amplification may result in the over expres-
sion of a transcription factor, which may in turn affect
the expression of hundred of genes in other chromo-
somes with or without imbalan c e s ,t h e r e f o r e ,o b s c u r i n g
direct from indirect effects. Moreover, structural analyses
do not take into account mutations in the genome that
may affect protein expression and function, nor the role
Figure 4 (A) (Left panel) self-organizing heat map based on the 968 delegate genes of 112 melanoma metastases; the solid yellow
lines define two classes discovered by this method referred subsequently as TARA’s classification. The dashed yellow line defines a
secondary class, sitting astride the two previous ones. Samples included in each class were named accordingly for subsequent class prediction
analyses. Rearrangement of sample (right panel) according to the 100 transcripts most significantly differentially expressed by class A metastases
compared to class B metastases demonstrated that the C class includes metastases prevalently but not exclusively close to the A class. (B) PCA
analysis based on the complete data set demonstrating the tri-dimensional distribution of the 112 melanoma metastases based on the TARA’s
classification. Top canonical pathways (C) and top Functions (D) enriched according to IPA when transcripts differentially expressed between
TARA’s class A vs class B were selected according to a t test(cutoff p-value < 0.001. (E) Self-organizing heat map of 112 melanoma metastases
based on transcripts known to be associated with the melanoma oncogenesis. (F) Self-organizing heat map of the same metastases based on
transcripts previously described to differential melanomas with poorer compared to better prognosis [8]; (G) Self-organizing heat map of the
same metastases based on genes representative of Th1 and Th17 immune phenotype [33,36-38].
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genomic areas may play on genes included in regions of
genomic imbalances.
Tumor cell lines are commonly employed to study prop-
erties of human cancer believed to be clinically relevant.
Although cell lines are not perfect because they do not
account for the influence of the tumor microenvironment,
matching in vivo and in vitro information provides a
powerful approach to describe highly conserved character-
istics that can be relevant to the oncogenic process; yet,
genome-wide comparisons between parental tumors and
cell line progeny are limited [23]. In this study, we had the
opportunity to compare the transcriptional profile of mel-
anoma cell lines with that of their parental tissue identify-
ing transcripts consistently expressed; there are several
reasons for transcriptional patterns to be discordant
between cell lines and parental tissues; transcripts
expressed by normal cell infiltrates are obviously missing;
moreover, cancer cell transcription in vitro is unaffected
by the crosstalk with other cells through paracrine secre-
tion or cell to cell contact; furthermore, as cultured cell
expand in vitro, cancer cell clones present at low fre-
quency in the parental tumor may take over in culture; in
particular, this in vitro natural selection may favor the
expansion of stem cell-like subcomponents of different
autologous tumors. Finally, the genetic drift due to the
instability of cancer may incrementally diverge transcrip-
tional patterns with subsequent in vitro passages. How-
ever, it is possible that properties driving the oncogenic
process may be insensitive to surrounding influences or to
time as they represent requirements for growth. Thus,
transcription of some genes may remain steady because
the neoplastic process depends upon them. Moreover,
gene expression may coincide in vivo and in vitro because
it is cancer-restricted though not causative as in the
expression of cancer testis antigens [42], melanoma differ-
entiation antigens [26,43] or kidney-specific transcripts
[44]. This study identified about 3,000 stably expressed
genes (Figure 2C) and the top 1,000 defined a tumor-spe-
cific finger print that accurately matched CMs with their
respective TMs. Functional interpretation demonstrated
that these genes were almost exclusively associated with
the oncogenic process while most cancer testis antigens
and melanoma differentiation antigens ranked lower in
the correlation scale (data not shown).
We then quantified the weight of genetic imbalances
on the stably expressed genes. One could suspect that a
gene stably expressed in vivo and in vitro and relevant to
oncogenesis may be more likely be expressed in concor-
dance with the corresponding genomic imbalance than
an irrelevant gene produced by infiltrating normal cells
such as interferon-g whose expression is likely dependent
upon environmental factors. Expanding stochastically on
this premise, one would predict a gradual decrease in
concordance between copy number and transcription
with decreasing stability of gene expression between CMs
and TMs. This was exactly what we observed (Figure 3A).
T oo u rk n o w l e d g e ,t h i si st h efirst compelling evidence
that genetic imbalances significantly influence the global
expression of the respective genes. Interestingly, this
influence is limited: the percent of genes expressed in
concordance with their copy number reached a plateau
of 32% at the minimal cutoff of significance (Pearson’s
correlation coefficient p-value < 0.05) and did not change
with increasing level of concordance between CMs and
TMs. Thus, this model allowed the detection and quanti-
fication of a genome/transcriptome axis representative of
stable properties of cancer cells inclusive of 968 tran-
scripts that we named “genomic delegates” as they repre-
sent at the transcriptional level the genetic footprint of
individual cancers.
When the genomic delegates were applied to a set of
112 consecutive melanoma metastases, two divergent phe-
notypes were observed with a third sitting astride; we
termed them TARA’s (transcriptional adjustments related
to amplification/deletion)c l a s sA ,Ba n dC .A l t h o u g h
these subclasses were “discovered” based on gene asso-
ciated with copy number variation and steadily expressed
in vivo and in vitro, it appears that they represent a natural
phenotype of melanoma that segregated separately also by
unsupervised testing adopting as a platform the complete
genome-wide data set (Figure 4B). Moreover, functional
analyses based on the selection of genes known to be rele-
vant to melanoma biology segregated the three classes
(with A and B representing the extremes): TARA’s class A
tumors prevalently expressed transcripts related to deregu-
lation of WNT and g-protein coupled signaling and cyclins
activity while class B aligned to a canonical activation of
the MAP kinase pathway and classic melanoma signaling
(Figure 4E). Furthermore, class A expressed transcripts
that we previously observed to be expressed in melanoma
with more invasive behavior such as WNT5A [8] or
MAGEA genes [31,32] while Class B was enriched with
transcripts associated with better prognosis [8] and the
expression of melanocytic lineage specific genes [43]
denoting a higher status of differentiation (Figure 4F).
Finally, TARA’s class A metastases displayed a classic
Th17 phenotype while class B a Th1; this finding is clini-
cally relevant as the two immune phenotypes have distinct
prognostic weight in cancer with the former being asso-
ciated with poor prognosis [22] and the latter with good
prognosis and likelihood to respond to immunotherapy
[33-35,45]. Analyses of the genetic differences among the
three classes of melanoma or among the respective cell
lines are being undertaken to identify regions of potential
interest for the identification of novel oncogenes or tumor
suppressor genes. Although the discovery through the
genomic delegates of at least two classes of metastatic
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the former; it is important to observe, how, such sub-clas-
sification stems, at least in part from the genetic backbone
of individual cancers and, therefore, clinically relevant
aspects of individual phenotypes may in the future be
traced back to genetic alterations that have been mapped
by this study.
Conclusions
The new classification of melanoma according to stably
expressed genes provided new insights about of clinical
relevance. It appears that TARA’s class B represents a sub-
type of melanoma more closely linked to the melanocytic
lineage while class A represents a more undifferentiated
and less melanoma-specific subtype enriched by the co-
ordinate activation of functions related to migration, tissue
regeneration and paracrine and autocrine signaling, a phe-
nomenon we previously described in an independent ana-
lysis of melanoma metastases [7]. More broadly, this study
provides evidence that clinically relevant phenotypes of
melanoma can be retraced to the genetic back bone of
individual cancer cells offering a tool for uncovering novel
targets for tailored anti-cancer therapy.
Methods
Melanoma cell culture
Melanoma cell lines were derived from metastatic mela-
noma lesions from patients treated at the Surgery Branch,
National Cancer Institute (NCI), Bethesda, MD kindly
donated by Dr Steven A Rosenberg. The cells we received
from Surgery Branch were after passage 3. Cells were cul-
tured in bulk at 37°C, in CO2 5% with RPMI 1640 medium
(Gibco) supplemented with 10% heat-inactivated Fetal
Bovine Serum (FBS, Cellgro), 0.01% L-glutamine Pen-
Strep Solution (GPS 100x, Gemini Bio-Products), 0.001%
Ciprofloxacin (10 mg/mL) and 0.01% Fungizone Ampho-
tericin B (250 μg/mL, Gibco). Confluent adhering cells
were washed twice with cold Phosphate Buffered Saline
1X (PBS pH 7.4, Gibco) and detached by exposure to 0.2%
Trypsin-EDTA (0.5%:0.53 mM Solution, Gemini Bio-Pro-
ducts). The obtained cell suspension was centrifuged to
remove cell debris and suspended in fresh medium to a
final concentration of 10
7cells/mL. Early-passage cultures
(< 10) were used for all experiments and no clonal sub
selection was performed.
Identity confirmation of cell lines and parental tissue by
HLA phenotyping
Genomic DNA was extracted using QIAamp
® DNA
Mini Kit (Qiagen) according to the manufacture’s proto-
col. DNA quality and quantity was estimated using
Nanodrop (Thermo Scientific). The HLA Class I pheno-
type of all cell lines and from normal autologous lym-
phocytes from the same patients was tested by HLA
Laboratory, Department of Transfusion Medicine,
National Institutes of Health, Bethesda (MD). The HLA
type of 15 cell lines out of the original 16 tested
matched perfectly according to the original HLA type of
the patients and therefore only 15 matched cell lines
(CM) were studied and compared with their respective
matched tumor samples (TM).
Microarray analysis
Total RNA from 15 cell line and autologous tumor pairs
plus another 97 heterologous melanoma metastases (total
112 melanoma metastases) from patients treated at the
Surgery Branch, NCI were extracted using miRNeasy
minikit (Qiagen) according to the manufacture’s protocol.
RNA quality and quantity was estimated using Nanodrop
(Thermo Scientific) and Agilent 2100 Bioanalyzer (Agilent
Technologies, Palo Alto, CA). First- and second-strand
cDNA were synthesized from 300 ng of total RNA accord-
ing to manufacturer’s instructions (Ambion WT Expres-
sion Kit). cDNAs were fragmented, biotinylated, and
hybridized to the GeneChip Human Gene 1.0 ST Arrays
(Affymetrix WT Terminal Labeling Kit). The arrays were
washed and stained on a GeneChip Fluidics Station 450
(Affymetrix); scanning was carried out with the GeneChip
Scanner 3000 and image analysis with the Affymetrix Gen-
eChip Command Console Scan Control. Expression data
were normalized, background-corrected, and summarized
using the RMA algorithm, http://www.partek.com/. Data
were log-transformed (base 2) for subsequent statistical
analysis. Cluster analysis was performed using Partek
software.
Array comparative genomic hybridization (CGH)
Human advanced melanoma cell lines were isolated and
1.5 μg genomic DNA extracted using QIAamp
® DNA
Mini Kit (Qiagen). For the healthy diploid reference,
1.5 μg genomic DNA was isolated from the PBMCs of a
healthy female donor using QIAamp
® DNA Mini Kit
(Qiagen). DNA fragmented, labeled, purified, and hybri-
dized to Agilent 2 × 105 K arrays according to the Agilent
Oligonucleotide Array-Based CGH for Genomic DNA
Analysis (version 6.2.1). Washing and scanning in Agilent
BioScanner B took place immediately after hybridization.
Data was extracted using Agilent’s Feature Extraction
Softward.
Statistical analysis
Copy Number Analysis was performed according to Partek
suggested parameters. Copy number variations are mea-
sured by two-color data comparing melanoma cell lines to
healthy diploid reference genomic DNA, and values are
reported as intensity log2 ratios. Amplifications were
defined as segments with log2 ratios greater than 0.15.
Deletions were defined as segments with log2 ratios less
Spivey et al. BMC Genomics 2012, 13:156
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Page 9 of 11than -0.3. Significantly different regions were determined
using the Segmentation Model algorithm of the Partek
Genomic Suite set to detect copy number states. Segments
were defined as regions that differed from neighboring
regions by at least 2 signal to noise ratios (SNRs) in at least
10 markers. Regions identified were annotated with gene
symbols by importing the annotation file from the NCBI
RefSeq genome browser (build Hg19).
All analyses were performed using Partek Genomic
Suite, BRB Array tool [46], or R package. Congruency of
gene expression among parental tissues and derivative cell
lines was assessed by correlation analysis using the Pear-
son correlation coefficient. Pearson correlation between
chromosomal copy number data and gene expression data
was performed within Partek software using the “Biologic
Integration/Correlating Gene Expression and Copy Num-
ber” function. DNA log2 ratio copy number variation data
was correlated with mRNA gene expression log2 ratios for
all 15 cell line samples. The threshold for Pearson correla-
tion significance for concordant data in this study was uni-
formly defined by p-value < 0.05. Tests for expression
differences between different classes were conducted for
individual genes using two-sided t tests, considering
P values of < 0.001 as significant, with adjustment for the
batch effect. Principal component analysis (PCA) was
applied for visualization when relevant based on the com-
plete data set. Heat maps are presented based on Partek
visualization programs. Gene interaction analyses were
executed using Ingenuity Pathways Analysis (IPA) tools
3.0 http://www.ingenuity.com.
Additional material
Additional file 1: Figure S1. Shows self-organizing heat map comparing
the distribution of molecularly matched TM (green)/CM (yellow) pairs
based on 109 transcripts selected from common cancer biomarkers [27],
melanoma restricted genes [26], cancer testis antigens [42] and
melanoma differentiation antigens [43]. Autologous samples are color
coded according to “sample ID”.
Additional file 2: Table S1. Is a table listing the 3,030, 1,006 transcripts
stably expressed by CMs and TMs and the 968 genomics delegates.
Additional file 3: Table S2. Is a table listing a number of identified
housekeeping genes selected according to the two referred paper
[28,29].
Additional file 4: Figure S2. Shows Self-organizing heat map genes of
112 melanoma metastases based on the expression of melanoma
differentiation antigens and representative cancer testis antigens.
Additional file 5: Table S3. Is a table listing selected gene-specific
sequencing and CGH results of cell lines ranked according to the
inclusion of their parental tumors into the three different TARA’s classes.
Abbreviations
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